Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 6—June 2014
Research

Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania

Stephen E. Schachterle1, George Mtove, Joshua P. Levens, Emily Clemens, Lirong Shi, Amrita Raj, J. Stephen Dumler, Beatriz Munoz, Shelia West, and David J. SullivanComments to Author 
Author affiliations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (S.E. Schachterle, L. Shi, A. Raj, D.J. Sullivan); National Institute for Medical Research, Ubwari, Tanzania (G. Mtove); Johns Hopkins University School of Medicine, Baltimore (J.P. Levens, E. Clemens, J.S. Dumler, B. Munoz, S. West)

Main Article

Figure 4

Effect of azithromycin (AZT) mass drug administration (MDA) in treatment and control villages over space and time, Tanzania, January 12–July 21, 2009. AZT MDA control villages (2, 5, 7, and 8) are shown on the left, and AZT MDA treatment villages (1, 3, 4, and 6) are shown on the right. Survey periods at baseline and month 1 are shown within treatment and control groups. Baseline infection and prevalent infections at month 1 (red circles) and negative tests (white circles) are shown. Spatial odd

Figure 4. Effect of azithromycin (AZT) mass drug administration (MDA) in treatment and control villages over space and time, Tanzania, January 12–July 21, 2009AZT MDA control villages (2, 5, 7, and 8) are shown on the left, and AZT MDA treatment villages (1, 3, 4, and 6) are shown on the rightSurvey periods at baseline and month 1 are shown within treatment and control groupsBaseline infection and prevalent infections at month 1 (red circles) and negative tests (white circles) are shownSpatial odds of Plasmodium falciparum (P.f.) infection are shown in areas of high odds of infection (red) and areas of low odds of infection (blue)Ln kernel smoothers were used to show spatial odds.

Main Article

1Current affiliation: Pfizer, Inc., New York, New York, USA.

Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external